Beyond the JCA template: A guide to leveraging EU JCA dossiers to optimize national market access

Beyond the JCA template

A guide to leveraging EU JCA dossiers to optimize national market access

JCAs are reshaping the HTA landscape across Europe, and health technology developers are learning how to work with the new process.

In this white paper, experts from OPEN Health explore the opportunities afforded by the JCA dossier to incorporate evidence, and context to support future national HTA and reimbursement discussions.

Featuring practical guidance for dossier development, the paper highlights opportunities to strengthen the interpretation of patient outcomes, treatment patterns, and real-world evidence, while remaining within the scope of the JCA.

We have reserved a copy of this white paper for you.

We are excited to share our latest thinking with you.

Please fill out the form to download the whitepaper.

By submitting your information, you agree to receive communications from OPEN Health. We will use your information in accordance with our Privacy Notice.


OPEN Health authors:
Florentin Köhnemann, PhD Senior Director | Strategic Market Access OPEN Health Evidence & Access

Florentin Köhnemann, PhD

Senior Director | Strategic Market Access

Adaeze Eze, MSc Associate Director | Strategic Market Access OPEN Health Evidence & Access

Adaeze Eze, MSc

Associate Director | Strategic Market Access OPEN Health Evidence & Access

Lisette Nientker, MSc Senior Director | Strategic Market Access OPEN Health Evidence & Access

Lisette Nientker, MSc

Senior Director | Strategic Market Access

Grace E. Fox, PhD Deputy Chief Scientific Officer | Strategic Market Access OPEN Health Evidence & Access

Grace E. Fox, PhD

Deputy Chief Scientific Officer | Strategic Market Access OPEN Health Evidence & Access


At OPEN Health, we connect visionary minds, pioneering science, and advanced technology to drive real impact.

By uniting people, science, and technology, we activate new opportunities for biopharma innovation. Our expertise across medical affairs and market access unlocks faster, smarter routes to market. We are committed to improving patient outcomes worldwide.

Talk to us